Expression and the Role of TFF3 in Lung Adenocarcinoma Based on Bioinformatics Analysis
10.11969/j.issn.1673-548X.2024.10.020
- VernacularTitle:基于生物信息学分析TFF3在肺腺癌中的表达和调控作用
- Author:
Zhiyuan WANG
1
;
Ling MENG
;
Juan SHI
Author Information
1. 250000 济南,山东第一医科大学(山东省医学科学院)临床与基础医学院人体解剖学教研室
- Keywords:
TFF3;
Lung adenocarcinoma;
Bioinformatics analysis;
Tumor immunity;
PI3K/Akt signaling pathway
- From:
Journal of Medical Research
2024;53(10):110-117,122
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the role of TFF3 in lung adenocarcinoma using bioinformatics methods and in vitro cell experi-ments.Methods We analyzed the characteristic differences between patient groups with high and low TFF3 expression using the TCGA database and R package.The analysis covered various perspectives,including clinical features,immune microenvironment,tumor muta-tion burden,and immunotherapy.The effect of TFF3 on the number of NCI-H1975 cells was determined using RTCA,while the expres-sion of the PI3K/Akt signaling pathway Akt and its activated state p-Akt was detected using Western blot.Results The expression of TFF3 increased in lung adenocarcinoma tissue,and this increase was related to the pathological type of lung adenocarcinoma.However,it was not associated with the prognosis of patients.Low expression of TFF3 was associated with low tumor purity.Additionally,TFF3 showed a negative correlation with tumor mutation burden and the expression of several immune checkpoint genes.In our study,we treated NCI-H1975 cells with TFF3 and observed an increase in the total number of cells.Furthermore,the results from Western blot analysis indicated that TFF3 could activate the expression of the p-Akt gene.Conclusion TFF3 could be upregulated in specific subtypes of lung adenocarcinoma and linked with tumor immunity of lung adenocarcinoma.We observed that TFF3 can enhance the growth of lung ad-enocarcinoma cells,possibly by activating the PI3K/Akt signaling pathway.Our findings suggest that TFF3 could serve as a promising therapeutic target for individuals diagnosed with lung adenocarcinoma.
